TransCode Therapeutics, Inc. (RNAZ)
Automate Your Wheel Strategy on RNAZ
With Tiblio's Option Bot, you can configure your own wheel strategy including RNAZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol RNAZ
- Rev/Share 0.0
- Book/Share 2133.946
- PB 0.0032
- Debt/Equity 0.0
- CurrentRatio 5.1976
- ROIC -0.0012
- MktCap 5751978.0
- FreeCF/Share -643.9808
- PFCF -0.0019
- PE -0.0028
- Debt/Assets 0.0
- DivYield 0
- ROE -4.7015
- Rating B-
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 5
- P/B Score 5
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
15 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with no evidence of disease progression PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement BOSTON , May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that the third patient in Cohort 4 of its Phase 1a clinical trial has received their initial dose of TTX-MC138. All cohorts have enrolled at least three patients who have been dosed …
Read More
TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer
Published: May 01, 2025 by: PRNewsWire
Sentiment: Neutral
A total of 13 patients treated with four escalating doses of TTX-MC138 No significant safety or dose limiting toxicities reported Two patients have so far maintained stable disease on treatment for at least seven months PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement BOSTON , May 1, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced further progress in its Phase 1a clinical trial of TTX-MC138 in patients with metastatic cancer. TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b, or …
Read More
All You Need to Know About TransCode Therapeutics (RNAZ) Rating Upgrade to Buy
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive
TransCode Therapeutics (RNAZ) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Read More
TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Published: March 23, 2025 by: PRNewsWire
Sentiment: Neutral
BOSTON , March 23, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that it has agreed to sell an aggregate of 10,250,000 shares of its common stock and warrants to purchase up to 10,250,000 shares of common stock priced at-the-market under Nasdaq rules, at a purchase price of $0.98 per share and associated warrant. The warrants will have an exercise price of $0.86 per share and will be immediately exercisable upon issuance for a period of five years following the date of issuance.
Read More
About TransCode Therapeutics, Inc. (RNAZ)
- IPO Date 2021-07-08
- Website https://www.transcodetherapeutics.com
- Industry Biotechnology
- CEO Mr. Thomas A. Fitzgerald M.B.A.
- Employees 7